Study: Copanlisib + rituximab slows relapsed indolent lymphoma
Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a …
Home »
Pembrolizumab Slows MSI-H-dMMR Metastatic CRC
THURSDAY, Dec. 3, 2020 — For the first-line treatment of microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer, pembrolizumab is …
Bionic pacemaker slows progression of heart failure
Using brain circuits made in silicon, scientists have alleviated symptoms of heart failure by reinstating the body’s natural heart rhythm. …
Drug combo slows progression in advanced breast cancer
(HealthDay)—Treatment with a combination of alpelisib and fulvestrant prolongs progression-free survival among patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal …